Join Reviva Pharmaceuticals for a virtual key opinion leader (KOL) event featuring Stephen R. Marder, MD (UCLA Psychosis Clinic) and Larry Ereshefsky, PharmD, BCPP, FCCP (University of Texas; Follow the Molecule LLC), who will join company management to discuss the unmet need and current treatment landscape for schizophrenia.

The event will review the full data set including long-term safety, tolerability and efficacy, as well as biomarker from the open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine (RP5063) in patients with schizophrenia. Brilaroxazine is Reviva’s novel serotonin dopamine signaling modulator of multi-faceted direct and indirect activities on critical pathways implicated in schizophrenia.

A live question and answer session will follow the formal presentations.